Articles

Poll

Podcasts

Slideshows

Videos

A look at 13 key FDA approvals from Q1 2026, highlighting advances in rare disease, pediatrics, novel therapies, and patient-centered innovation.

Q1 2026 Recap: Top FDA Approvals

Martinez discusses unmet needs in pruritus management and maralixibat’s potential to expand treatment of itch across rare cholestatic liver diseases.

Expanding the Reach of Maralixibat in Rare Cholestatic Liver Diseases, With Mercedes Martinez, MD

The IBAT inhibitor’s approval, the first for this indication, was based on data from the GLISTEN trial showing reductions in cholestatic pruritus and itch-related sleep interference.

FDA Approves Linerixibat (Lynavoy) As First Treatment for Cholestatic Pruritus in PBC

AI-enabled ECG may help detect liver disease earlier, offering a new path to close diagnostic gaps and shift toward preventive hepatology in clinical practice.

Improving Early Liver Disease Diagnosis With AI ECG, With Doug Simonetto, MD

An audio recap of the top 5 stories in healthcare news from the week of 03/02-03/08.

HCPLive 5 Stories in Under 5: Week of 03/08

With new therapies emerging for hepatitis D, Kushner discusses brelovitug’s potential and what will be learned from the phase 3 AZURE program.

Inside the AZURE Program of Brelovitug for Hepatitis D, With Tatyana Kushner, MD

Kushner discusses the global burden of hepatitis D, gaps in testing, and emerging therapies reshaping the treatment landscape.

New Momentum in Hepatitis D Research and Treatment, With Tatyana Kushner, MD

A trio of experts discuss how simplifying hepatitis B guidance could help more clinicians diagnose, treat, and support patients living with chronic infection.

Empowering More Clinicians to Treat Hepatitis B

In this segment of Liver Lineup, experts discuss the complexity of hepatitis B guidelines and why it’s important to empower clinicians and expand care beyond specialists.

Are We Making Hepatitis B Treatment Too Complicated?

New research suggests MASLD risk may develop early in life, highlighting the impact of parental factors and cumulative childhood adiposity.

Understanding Intergenerational Risk Factors for MASLD, With Stefani Tica, MD, MPH

Alpha-1 antitrypsin deficiency

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Hepatology